Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 13, 2004 - Issue 12
Submit an article Journal homepage
98
Views
14
CrossRef citations to date
0
Altmetric
Review

Amyotrophic lateral sclerosis: contemporary concepts in etiopathogenesis and pharmacotherapy

Michael J Strong UC-LHSC, Room 7 OF10, 339 Windermere Road, London, Ontario, Canada. [email protected]
Pages 1593-1614 | Published online: 24 Feb 2005

Bibliography

  • CHARCOT JM, JOFFROY A: Deux cas d'atrophie musculaire progressive avec lesions de la substance grise et des faisceaux antérolatéraux de la moelle épinière. Arch. Physiol Norm. Pathol (1869) 2:354–744.
  • ARAN FA: Recherches sur une maladie non encore décrite du systéme musculaire (atrophie musculaire progressive). Arch. Gen. Med. (1850) 24:5–35.
  • ARAN FA: Recherches sur une maladie non encore décrite du systéme musculaire (atrophie musculaire progressive) (2e article - suite et fin). Arch. Gen. Med. (1850) 24:172–214.
  • RIGGS JE: Longitudinal gompertzian analysis of amyotrophic lateral sclerosis mortality in the US, 1977-1986: evidence for an inherently susceptible population subset. Mech. Ageing Dev. (1990) 55:207–220.
  • LILIENFELD DE, EHLAND J, LANDRIGAN PJ et al: Rising mortality from motoneuron disease in the USA, 1962-84. Lancet (1989) 1:710–713.
  • WORMS PM: The epidemiology of motor neuron diseases: a review of recent studies. Neurol Sci. (2001) 191:3–9.
  • BRUIJN LI, MILLER TM, CLEVELAND DW: Unraveling the mechanisms involved in motor neuron degeneration in ALS. Ann. Rev Neurosci. (2004) 27:723–749.
  • KURLAND LT, MULDER DW: Epidemiological investigations of amyotrophic lateral sclerosis. 1. Preliminary report on geographic distribution, with special reference to the Mariana Islands, including clinical and pathological observations. Neurology (1954) 4:355–448.
  • GAJDUSEK DC, SALAZAR AM: Amyotrophic lateral sclerosis and parkinsonian syndromes in high incidence among the Auyu and Jakai people of West New Guinea. Neurology (1982) 32:107–126.
  • GARRUTO RM, YANAGIHARA R, GAJDUSEK DC: Disappearance of high-incidence amyotrophic lateral sclerosis and parkinsonism-dementia on Guam. Neurology (1985) 35:193–198.
  • KOERNER DR: Amyotrophic lateral sclerosis on Guam: a clinical study and review of the literature. Ann. Intern. Med. (1952) 24:1204–1220.
  • CHEN K-M, BRODY JA, KURLAND LT: Patterns of neurological diseases on Guam. I. Epidemiological aspects. Arch. Nemo] (1968) 19:573–578.
  • REED DM, BRODY JA: Amyotrophic lateral sclerosis and parkinsonism-dementia on Guam, 1945-1972. I. Descriptive epidemiology. Am.' Epidemiol (1975) 101:287–301.
  • GARRUTO RM, GAJDUSEK DC, CHEN KM: Amyotrophic lateral sclerosis among Chamorro migrants from Guam. Ann. Neurol (1980) 8:612–619.
  • TORRES J, IRIARTE LLG, KURLAND LT: Amyotrophic lateral sclerosis among Guamanians in California. Calif. Med. (1957) 86:385–388.
  • YANAGIHARA RT, GARRUTO RM, GAJDUSEK DC: Epidemiological surveillance of amyotrophic lateral sclerosis and parkinsonism-dementia in the Commonwealth of the Northern Mariana Islands. Ann. Neurol (1983) 13:79–86.
  • COX PA, BANACK SA, MURCH SJ: Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc. Natl. Acad. Sci. USA (2003) 100:13380–13383.
  • HUDSON AJ, DAVENPORT A, HADER WJ: The incidence of amyotrophic lateral sclerosis in southwestern Ontario, Canada. Neurology (1986) 36:1524–1528.
  • HORNER RD, KAMINS KG, FEUSSNER JR et al: Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology (2003) 61:742–749.
  • HALEY RW: Excess incidence of ALS in young Gulf War veterans. Neurology (2003) 61:750–756.
  • ROSE MR: Gulf War syndrome is an uncertain trigger for ALS. Neurology (2003) 61:730–731.
  • NELSON LM, McGUIRE V, LONGSTRETH WT Jr, MATKIN C: Population-based case-control study of amyotrophic lateral sclerosis in western Washington state. I. Cigarette smoking and alcohol consumption. Am. Epidemiol (2000) 151:156–163.
  • •A well-conducted epidemiological study examining the roles of smoking and diet as risk factors for ALS.
  • NELSON LM, MATKIN C, LONGSTRETH WT Jr, McGUIRE V: Population-based case control study of amyotrophic lateral sclerosis in western Washington State. II. Diet. Am. J. Epidemiol (2000) 151:164–173.
  • •A well-conducted epidemiological study examining the roles of smoking and diet as risk factors for ALS.
  • STRONG MJ. Exogenous neurotoxins. In: Amyotrophic Lateral Sclerosis. RH Brown Jr, V Meininger, M Swash (Eds), Martin Dunitz Ltd., London, UK (2000):279–287.
  • MAJOOR-KRAKAUER D, WILLEMS PJ, HOFMAN A: Genetic epidemiology of amyotrophic lateral sclerosis. Clin. Genet. (2003) 63:83–101.
  • STRONG MJ: Simplifying the approach: what can we do? Neurology (1999) 53:S31–S34.
  • STRONG MJ: Biochemical markers. Amyotroph. Lateral Scler. Other Motor. Neuron. Disord (2002) 3\(Suppl. 1):583–586.
  • CHEN R, GRAND'MAISON F, STRONG MJ, RAMSAY DA, BOLTON CF: Motor neuron disease presenting as acute respiratory failure: a clinical and pathological study. Nemo] Neurosurg. Psychiat. (1996) 60:455–458.
  • SWASH M, DESAI J, MISRA VP: What is primary lateral sclerosis?' Neurol Sci. (1999) 170:5–10.
  • ROWLAND LP: Primary lateral sclerosis: disease, syndrome, both or neither? Nemo] Sci. (1999) 170:1–4.
  • KUIPERS-UPMEIJERJ, DE JAGER AEJ, HEW JM, SNOEK JVV, VAN WEERDEN TW: Primary lateral sclerosis: clinical, neurophysiological, and magnetic resonance findings. Neurol Neurosurg. Psychiat. (2001) 71:615–620.
  • LE FORESTIER N, MAISONOBE T, PIQUARD A et al.: Does primary lateral sclerosis exist? A study of 20 patients and a review of the literature. Brain (2001) 124: 1989-1999.
  • EISEN A, SCHULZER M, MacNEIL M, PANT B, MAK E: Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve (1993) 16:27–32.
  • HIRAYAMA K, TOM ONAGA M, KITANO K et al.: Focal cervical poliopathy causing juvenile muscular atrophy of distal upper extremity: a pathological study. Nemo] Neurosurg. Psychiat. (1987) 50:285–290.
  • SOBUE I, SAITO N, IIDA M, ANDO K: Juvenile type of distal and segmental muscular atrophy of upper extremities. Ann. Neurol (1978) 3:429–432.
  • GOURIE-DEVI M, TURUVEKERT GS, SHANKAR SK: Monomelic amyotrophy. Arch.Neurol. (1984) 41:388–394.
  • ORYEMA J, ASHBY P, SPIEGEL S: Monomelic amyotrophy. Can. I Neurol Sci. (1990) 17:124–130.
  • HU MTM, ELLIS CM, AL-CHALABI A, LEIGH PN, SHAW CE: Flail arm syndrome: a distinctive variant of amyotrophic lateral sclerosis. J. Neurol Neurosurg. Psychiat. (1998) 65:950–951.
  • COURATIER P, TRUONG CT, KHALIL M, DEVIERE F, VALLAT JM: Clinical features of flail arm syndrome. Muscle Nerve (2000) 23:646–648.
  • WORLD FEDERATION OF NEUROLOGY RESEARCH GROUP ON NEUROMUSCULAR DISEASE: El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J. Neurol Sci. (1994) 124(Suppl.):96–107.
  • TRAYNOR BJ, CODD MB, CORR B et al.: Amyotrophic lateral sclerosis mimic syndromes. Arch. Neurol (2000) 57:109–113.
  • BELSH JM, SCHIFFMAN PL: The amyotrophic lateral sclerosis (ALS) patient perspective on misdiagnosis and its repercussions. J. Neurol Sci. (1996) 139:110–116.
  • STRONG MJ, GRACE GM, ORANGE JB, LEEPER HA: Cognition, language and speech in amyotrophic lateral sclerosis: a review. J. Clin. Exp. Neuropsych. (1996) 18:291–303.
  • STRONG MJ, LOMEN-HOERTH C, CASELLI RJ, BIGIO EH, YANG W: Cognitive impairment, FTD and motor neuron disease. Ann. Neurol (2003) 54:S20–S23.
  • STRONG MJ, GRACE GM, ORANGE JB et al.: A prospective study of cognitive impairment in ALS. Neurology (1999) 53:1665–1670.
  • ••A detailed prospective study of cognitionin SALS defining alterations in verbal praxis and fluency as key markers.
  • MASSMAN PJ, SIMS J, COOKE N et al.: Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis. J. Neurol Neurawrg. Psych/at. (1996) 61:450–455.
  • LOMEN-HOERTH C, MURPHY J, LANGMORE S et al.: Are Amyotrophic Lateral Sclerosis patients cognitively normal? Neurology (2003) 60:1094–1097.
  • ••A key study examining the frequency of cognitive dysfunction, and its clinical characteristics, in SALS.
  • STRONG MJ, HUDSON AJ, ALVORD WG: Familial amyotrophic lateral sclerosis, 1850-1989: a statistical analysis of the world literature. Can. J. Neurol Sci. (1991) 18:45–58.
  • ROSEN DR, SIDDIQUE T, PATTERSON D et al: Mutations in Cu! Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 362:59–62.
  • CUDKOWICZ ME, MeKENNA-YASEK D, SAPP PE et al: Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann. Neurol (1997) 41:210–221.
  • ANDERSEN PM, FORSGREN L, BINZER M et al.: Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain (1996) 119:1153–1172.
  • ANDERSEN PM, NILSSON P, KER./NEN M-L et al.: Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia. Brain (1997) 120:1723–1737.
  • CHANCE PF, RABIN BA, RYAN SG et al.: Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. Am. J. Hum. Genet. (1998) 62:633–640.
  • CHEN Y-Z, BENNETT CL, HUYNH HM et al.: DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am. .1. Hum. Genet. (2004) 74:1128–1135.
  • RABIN BA, GRIFFIN JW, CRAIN BJ et al.: Autosomal dominant juvenile amyotrophic lateral sclerosis. Brain (1999) 122:1539–1550.
  • HULETTE CM, PERICAK-VANCE MA, ROSES AD et al: Neuropathological features of frontotemporal dementia and parkinsonism linked to chromosome 17q21-22 (FTDP-17): Duke family 1684. Neuropathol Exp. Neurol (1999) 58:859–866.
  • LYNCH T, SANO M, MARDER KS et al: Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology (1994) 44: 1878-1884.
  • YANG Y, HENTATI A, DENG H-X et al: The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet. (2001) 29:160–165.
  • HADANO S, HAND CK, OSUGA H et al.: A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet. (2001) 29:166–173.
  • FIGLEWICZ DA, KRIZUS A, MARTINOLI MG et al.: Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum. Ma Genet. (1994) 3:1757–1761.
  • AL-CHALABI A, ANDERSEN PM, NILSSON D et al.: Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum. Ma Genet. (1999) 8:157–164.
  • ROOKE K, FIGLEWICZ DA, HAN FY, ROULEAU GA: Analysis of the KSP repeat of the neurofilament heavy subunit in familial amyotrophic lateral sclerosis. Neurology (1996) 46:789–790.
  • TOMKINS J, USHER P, SLADE JY et al.:Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS). NeuroReport (1998) 9:3697–3670.
  • MEYER MA, POTTER NT: Sporadic ALS and chromosome 22: evidence for a possible neurofilament gene defect. Muscle Nerve (1995) 18:536–539.
  • BORTHWICK GM, JOHNSON MA, INCE PG, SHAW PJ, TURNBULL DM: Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann. Neurol (1999) 46:787–790.
  • LIN C-LG, BRISTOL LA, JIN L et al: Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron (1998) 20:589–602.
  • TROTTI D, ROLES A, DANBOLT NC, BROWN RH, Jr, HEDIGER MA: SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial 1606 glutamate transporter. Nat. Neurosciences (1999) 2:427–433.
  • CORCIA P, MAYEUX-PORTAS V, KHORIS J et al.: Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis. Ann. Neurol (2002) 51:243–246.
  • JACKSON M, MORRISON KE, AL-CHALABI A, BAKKER M, LEIGH PN: Analysis of chromosome 5q13 genes in amyotrophic lateral sclerosis: homozygous NAIP deletion in a sporadic case. Ann. Neurol (1996) 39:796–800.
  • ROBERTSON J, BEAULIEU J-M, DOROUDCHI MM et al: Apoptotic death of neurons exhibiting peripherin aggregates is mediated by the proinflammatory cytokine tumor necrosis factor-a. Cell Biol. (2001) 155:217–226.
  • ROBERTSON J, DOROUDCHI MM, NGUYEN MD et al: A neurotoxic peripherin splice variant in a mouse model of ALS. 'Cell Biol. (2003) 160:939–949.
  • SIDDONS MA, PICKERING-BROWN SM, MANN DMA, OWEN F, COOPER PN: Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis. Neurosci. Lett. (1996) 208:65–68.
  • AL-CHALABI A, ENAYAT ZE, BAKKER MC et al.: Association of apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease. Lancet (1996) 347:159–160.
  • DRORY VE, BIRNBAUM M, KORCZYN AD, CHAPMAN J: Association of APOE E4 allele with survival in amyotrophic lateral sclerosis. Neurol Sci. (2001) 190:17–20.
  • BACHUS R, BADER S, GESSNER R, LUDOLPH AC: Lack of association of apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease. Ann. Neurol (1997) 41:417.
  • SMITH RG, HAVERKAMP LJ, CASE S, APPEL V, APPEL SH: Apolipoprotein E epsilon 4 in bulbar-onset motor neuron disease. Lancet (1996) 348:334–335.
  • LAWYER T, NETSKY MG: Amyotrophic lateral sclerosis. Arch. Neurol (1963) 8:117–127.
  • BROWNELL B, OPPENHEIMER DR, HUGHES JT: The central nervous system in motor neurone disease. Neurol Neurosurg. Psychiat. (1970) 33:338–357.
  • HIRANO A: Cytopathology of amyotrophic lateral sclerosis. In: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. LP Rowland (Ed.), Raven Press, New York, NY, USA (1991):91–101.
  • WHARTON S, INCE PG: Pathology of motor neuron disorders. In: Motor Neuron Disorders. PJ Shaw, MJ Strong (Eds), Butterworth Heinemann, Philadelphia, PA, USA (2003):17–50.
  • CARPENTERS: Proximal axonal enlargement in motor neuron disease. Neurology (1968) 18:841–851.
  • DELISLE MB, CARPENTERS: Neurofibrillary axonal swellings and amyotrophic lateral sclerosis.' Neurol Sci. (1984) 63:241–250.
  • AVERBACK P: Unusual particles in motor neuron disease. Arch. Pathol Lab. Med. (1981) 105:490–493.
  • MIGHELI A, PEZZULO T, ATTANASIO A, SCHIFFER D: Peripherin immunoreactive structures in amyotrophic lateral sclerosis. Lab. Invest. (1993) 68:185–191.
  • WONG N, HE BP, STRONG MJ: Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis (ALS). Neuropatbol Exp. Neurol (2000) 59:972–982.
  • STRONG MJ: Neurofilament metabolism in sporadic amyotrophic lateral sclerosis. Neurol ScL (1999) 169:170–177.
  • MURAYAMA S, MORI H, IHARA Y et al.: Immunocytochemical and ultrastructural studies of lower motor neurons in amyotrophic lateral sclerosis. Ann. Neurol (1990) 27:137–148.
  • LEIGH PN, DODSON A, SWASH M, BRION J-P, ANDERTON BH: Cytoskeletal abnormalities in motor neuron disease. An immunohistochemical study. Brain (1989) 112:521–535.
  • WILSON CM, GRACE GM, MUNOZ DG, HE BP, STRONG MJ: Cognitive impairment in sporadic ALS. A pathological continuum underlying a multisystem disorder. Neurology (2001) 57:651–657.
  • YANG W, SOPPER MM, LEYSTRA-LANTZ C, STRONG MJ: Microtubule-associated tau protein positive neuronal and glial inclusions in amyotrophic lateral sclerosis. Neurology (2003) 61:1766–1773.
  • •A key study defining the cognitive impairment of ALS as being a tauopathy.
  • JACKSON M, LENNOX G, LOWE J: Motor neuron disease-inclusion dementia. Neurodegeneration (1996) 5:339–350.
  • SCHWAB C, STEELE JC, McGEER PL: Neurofibrillary tangles of Guam parkinson-dementia are associated with reactive microglia and complement proteins. Brain Res. (1998) 707:196–205.
  • LAMPSON LA, KUSHNER PD, SOBEL RA: Strong expression of class II major histocompatibility complex (MHC) antigens in the absence of detectable T cell infiltration in amyotrophic lateral sclerosis (ALS) spinal cord. I Neuropathol Exp. Neurol (1988) 47:353.
  • LAMPSON LA, KUSHNER PD, SOBEL RA: Major histocompatibility complex antigen expression in the affected tissues in amyotrophic lateral sclerosis. Ann. Neurol (1990) 28:365–372.
  • TROOST D, VAN DEN OORD JJ, VIANNEY DE JONG JMB: Immunohistochemical characterization of the inflammatory infiltrate in amyotrophic lateral sclerosis. Neuropathol Appl. Neurobiol (1990) 16:401–410.
  • KAWAMATA T, AKIYAMA H, YAMADA T, McGEER PL: Immunological reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. j Pathol (1992) 140:691–707.
  • TROOST D, CLAESSEN N, VAN DEN OORD JJ, SWAAB DF, DEJONG JMBV: Neuronophagia in the motor cortex in amyotrophic lateral sclerosis. Neuropatbol. Appl Neurobiol (1993) 19:390–397.
  • McGEER PL, McGEER EG, KAWAMATAT, YAMADA T, AKIYAMA H: Reactions of the immune system in chronic degenerative neurological diseases. Can. I Neurol Sci. (1991) 18:376–379.
  • SITTE HH, WANSCHITZ J, BUDKA H,BERGER ML: Autoradiography with [3H]PK11195 of spinal tract degeneration in amyotrophic lateral sclerosis. Acta Neuropathol (2002) 101:75–78.
  • AKIYAMA H, NISHIMURA T, KONDO H et al.: Expression of the receptor for macrophage colony stimulating factor by brain microglia and its upregulation in brains of patients with 1607 Expert Op/n. lnvestig. Drugs (2004) 13(12) Alzheimer's disease and amyotrophic lateral sclerosis. Brain Res. (1994) 639:171–174.
  • OBAL I, JAKAB JSK, SIKLOS L, ENGELHARDT JI: Recruitment of activated microglia cells in the spinal cord of mice by ALS IgG. NeuroReport (2001) 12:2449–2452.
  • KRIEGER C, PERRY TL, ZILTENER HJ: Amyotrophic lateral sclerosis: interleukin-6 levels in cerebrospinal fluid. Can. .1. Neurol. Sci. (1992) 19:357–359.
  • SEKIZAWA T, OPENSHAW H, OHBO K et al.: Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. Neurol. Sci. (1998) 154:194–199.
  • ALMER G, GUEGAN C, TEISMANN P et al.: Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann. Neurol. (2001) 49:176–185.
  • SHIBATA N, NAGAI R, UCHIDA K et al.: Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res. (2001) 917:97–104.
  • POLONI M, FACCHETTI D, MAT R et al.: Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci. Lett. (2000) 287:211–214.
  • BOILLEE S, VIALA L, PESCHANSKI M, DREYFUS PA: Differential microglial response to progressive neurodegeneration in the murine mutant Wobble]: Glia (2001) 33:277–287.
  • MENNINI T, BIGINI P, CAGNOTTO A et al.: Glial activation and TNFR-1 upregulation precedes motor dysfunction in the spinal cord of MND mice. Cytokine (2004) 25:127–135.
  • GHEZZI P, BERNARDINI R, GIUFFRIDA R et al: Tumor necrosis factor is increased in the spinal cord of an animal model of motor neuron degeneration. Ear. Cytokine Network (1998) 9:139–144.
  • HALL ED, OOSTVEEN JA, GURNEY ME: Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia (1998) 23:249–256.
  • ELLIOTT JL: Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. [Viol. Brain Res. (2001) 95:172–178.
  • ALEXIANU ME, KOZOVSKA M, APPEL SH: Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology (2001) 57:1282–1289.
  • YOSHIHARA H, ISHIGAKI S, YAMAMOTO M et al.: Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. Neurochem. (2002) 80:158–167.
  • HENSLEY K, FLOYD RA, GORDON B et al.: Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G39A-SOD1 mouse model of amyotrophic lateral sclerosis. Neurochem. (2002) 82:365–374.
  • HENSLEY K, FEDYNYSHYN J, FERRELL S et al.: Message and protein-level elevation of tumor necrosis factor a (TNFa) and TNFa-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol. Dis. (2003) 14:74–80.
  • DRACHMAN DB, ROTHSTEIN JD: Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis. Ann. Neurol. (2000) 48:792–795.
  • KRIZ J, NGUYEN MD, JULIEN J-P: Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. (2002) 10:268–278.
  • ZHU S, STAVROVSKAYA IG, DROZDA M et al.: Minocycline inhibits cytochrome crelease and delays progression of amyotrophic lateral sclerosis in mice. Nature (2002) 417:74–78.
  • VAN DEN BOSCH L, TILKIN P, LEMMENS G, ROBBERECHT W: Minocycline delays disease onset and mortality in a transgenic model of ALS. NeuroReport (2002) 13:1067–1070.
  • WU DC, JACKSON-LEWIS V, VILA M et al.: Blockade of microglial activation is neuroprotective in the 1-methy1-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci. (2002) 22:1763–1771.
  • YRJANHEIKKI J, KEINANEN R, PELLIKKA M, HOKFELT T, KOISTINAHO J: Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Sci. USA (1998) 95:15769–15774.
  • YRJANHEIKKI J, TIKKA T, KEINANEN R et al.: A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Nati Acad. Sci. USA (1999) 96:13496–13500.
  • ROTHSTEIN JD: Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. In: Pathogenesis and therapy of arnyodophic lateral sclerosis G Serratrice, T Munsat (Eds), Lippincott-Raven Publishers, Philadelphia, PA, USA (1995):7–20.
  • ROTHSTEIN JD, JIN L, DYKES-HOBERG M, KUNCL RW: Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Nati Acad. Sci. USA (1993) 90:6591–6595.
  • CARRIEDO SG, YIN HZ, WEISS JH: Motor neurons are selectively vulnerable to AMPA/Kianate receptor-mediated injury in vitro. Neurosci. (1996) 16:4069–4079.
  • ROTHSTEIN JD, TSAI G, KUNCL RW et al.: Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann. Neurol. (1990) 28:18–25.
  • SHAW PJ, FORREST V, INCE PG, RICHARDSON JP, WASTELL HJ: CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration (1995) 4:209–216.
  • SPREUX-VAROQUAUX 0, BENSIMON G, LACOMBLEZ L et al: Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. I Neurol. Sci. (2002) 193:73–78.
  • ROTHSTEIN JD, VAN KAMMEN M, LEVEY Al, MARTIN LJ, KUNCL RW: Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. (1995) 38:73–84.
  • SANELLI T, SOPPER MM, STRONG MJ: Sequestration of nNOS in neurofilamentous aggregate bearing neurons leads to enhanced glutamate-mediated calcium influx. Brain Res. (2004) 1004:8–17.
  • JACKSON M, STEERS G, LEIGH PN, MORRISON KE: Polymorphisms in the glutamate transporter gene EAAT2 in European ALS patients. Nemo] (1999) 246:1140–1144.
  • MEYER T, LENK U, KUTHER G et al: Studies of the coding region of the neuronal glutamate transporter gene in amyotrophic lateral sclerosis. Ann. Neurol (1995) 37:817–819.
  • MEYER T, MUNCH C, VOLKEL H, BOOMS P, LUDOLPH AC: The EAAT2 (GLT-1) gene in motor neuron disease: absence of mutations in amyotrophic lateral sclerosis and a point mutation in patients with hereditary spastic paraplegia. Nemo] Neurosurg. Psychiat. (1998) 65:594–596.
  • VARTIAINEN N, TIKKA T, KEINANEN R, CHAN PH, KOISTINAHO J: Glutamatergic receptors regulate expression, phosphorylation and accumulation of neurofilaments in spinal cord neurons. Neuroscience (1999) 93:1123–1133.
  • BERGERON C, PETRUNKA C, WEYER L: Copper/zinc superoxide dismutase expression in the human nervous system. Correlation with selective neuronal vulnerability. Am. J. Pathol (1996) 148:273–279.
  • BECKMAN JS: The double edged role of nitric oxide in brain function and superoxide-mediated injury. Dev. Physiol (1991) 15:53–59.
  • WIEDAU-PAZOS M, GOTO JJ, RABIZADEH S et al: Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science (1996) 271:515–518.
  • VAN DER VLIET A, O'NEILL CA, HALLI WELL B, CROSS CE, KAUR H: Aromatic hydroxylation and nitration of phenylalanine and tyrosine by peroxynitrite. FEBS Lett. (1994) 339:89–92.
  • ISCHIROPOULOS H, ZHU L, CHEN J et al.: Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochein. Biophys. (1992) 298:431–437.
  • BECKMAN JS, ISCHIROPOULOS H, ZHU L et al.: Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite. Arch. Biochein. Biophys. (1992) 298:438–445.
  • BECKMAN JS, CROW JP: Pathological implications of nitric oxide, superoxide and peroxynitrite formation. Biochein. Soc. Trans. (1993) 21:330–334.
  • JULIEN J-P: Amyotrophic lateral sclerosis: unfolding the toxicity of the misfolded. Cell (2001) 104:581–591.
  • BRUIJN LI, HOUSE WEART MK, KATO S et al.: Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science (1998) 281: 1851-1854.
  • •A important observation regarding the role of mutant SOD1 in forming neurotoxic aggregates.
  • CLEVELAND DW: From charcot to S OD1: mechanism of selective motor neuron death in ALS. Neuron (1999) 24:515–520.
  • REAUME AG, ELLIOTT JL, HOFFMAN EK et al.: Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. (1996) 13:43–47.
  • BEAL FM, FERRANTE RJ, BROWNE SE et al.: Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann. Nemo] (1997) 42:646–654.
  • ••A key paper demonstrating, in chimericanimals, the role of non-neuronal cells as critical determinants of the extent of motor neuronal loss in mutant SOD1-expressing transgenics.
  • STRONG MJ, SOPPER MM, CROW JP, STRONG WL, BECKMAN JS: Nitration of the low molecular weight neurofilament (NFL) is equivalent in sporadic amyotrophic lateral sclerosis and control cervical spinal cord. Biochein. Biophys. Res. Comm. (1998) 248:157–164.
  • CROW JP, YE YZ, STRONG MJ et al: Superoxide dismutase catalyzes nitration of tyrosines by peroxynitrite in the rod and head domains of neurofilament-L. Neurochem. (1997) 69:1945–1953.
  • ESTÈVEZ AG, CROW JP, SAMPSON JB et al.: Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science (1999) 286:2498–2500.
  • FACCHINETTI F, SASAKI M, CUTTING FB et al.: Lack of neuronal nitric oxide synthase in the pathogenesis of a transgenic mouse model of familial amyotrophic lateral sclerosis. Neuroscience (1999) 90:1483–1492.
  • KONG J, XU Z: Overexpression of neurofilament subunit NF-L and NF-H extends survival of a mouse model of amyotrophic lateral sclerosis. Neurosci. Lett. (2001) 281:72–74.
  • COUILLARD-DESPRES S, ZHU Q, WONG PC et al.: Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase. Proc. Natl. Acad. Sci. USA (1998) 95:9626–9630.
  • SUBRAMANIAM JR, LYONS WE, LIU J et al.: Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading. Nat. Neurosci. (2002) 5:301–307.
  • DURHAM HD, ROY J, DONG L, FIGLEWICZ DA: Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. I Neuropathol Exp. Nemo] (1997) 56:523–530.
  • LINO MM, SCHNEIDER C, CARONI P: Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. Neurosci. (2002) 22:4825–4832.
  • CLEMENT AM, NGUYEN MD, ROBERTS EA et al: Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science (2003) 302:113–117.
  • LIU J, LILLO C, JONSSON PA et al: Toxicity from familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron (2004) 43:5–17.
  • PASINELLI P, BELFORD ME, LENNON J et al.: Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bc1-2 in spinal cord mitochondria. Neuron (2004) 43:30.
  • FERRANTE RJ, BROWNE SE, SHINOBU LA et al: Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. Neurochem. (1997) 69:2064–2074.
  • BOWLING AC, SCHULZ JB, BROWN RH Jr, BEAL MF: Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. Neurochem. (1993) 61:2322–2325.
  • SHAW PJ, INCE PG, FALKOUS G, MANTLE D: Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann. Nemo] (1995) 38:691–695.
  • PEDERSEN WA, FU W, KELLER JN et al.: Protein modification by the lipid perwddation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann. Neurol (1998) 44:824.
  • SHIBATA N, NAGAI R, MIYATA S et al: Nonoxidative protein glycation is implicated in familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Acta NeuropathoL (2000) 100:275–284.
  • KATO S, HORIUCHI S, LIU J et al: Advanced gylcation endproduct-modified superoxide dismutase-1 (SOD-1)-positive inclusions are common to familial amyotrophic lateral sclerosis patients with SOD1 gene mutations and transgenic mice expressing human SOD1 with a G85R mutation. Acta NeuropathoL (2000) 100:490–505.
  • CHOU SM, WANG HS, TANIGUCHI A, BUCALA R: Advanced glycation endproducts in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis. Ma Med. (1998) 4:324–332.
  • CHOU SM, WANG HS, KOMAI K: Colocalization of NOS and SOD1 in neurofilament accumulation within motor neurons of amyotrophic lateral sclerosis: an immunohistochemical study. J. Chem. NeuroanaL (1996) 10:249–258.
  • SHIBATA N, HIRANO A, KOBAYASHI M et al.: Presence of Cu/Zn superoxide dismutase (SOD) immunoreactivity in neuronal hyaline inclusions in spinal cords from mice carrying a transgene for Gly93Ala mutant human Cu/Zn SOD. Acta Neuropathol (1998) 95:136–142.
  • CHOU SM, WANG HS, TANIGUCHI A: Role of SOD-1 and nitric oxide/cyclic GMP cascade on neurofilament aggregation in ALS/MND. Neural. ScL (1996) 139:16–26.
  • CASTAGNE V, GAUTSCHI M, LEFEVRE K, POSADA A, CLARKE PGH: Relationships between neuronal death and the cellular redox staus. Focus on the developing nervous system. Frog. Neurobiol (1999) 59:397–423.
  • PHILBERT MA, BEISWANGER CM, MANS ON MM et al.: Glutathione 5-transferase and gamma-glutamyl transpeptidase in the rat nervous systems: a basis for differential susceptibility to neurotoxicants. Neurotoxicology (1995) 16:349–362.
  • ROY J, MINOTTI S, DONG L, FIGLEWICZ DA, DURHAM HD: Glutamate potentiates the toxicity of mutant Cu/Zn-superoxide dismutase in motor neurons by postsynaptic calcium- dependant mechanisms. J. Neurosci. (1998) 18:9673–9684.
  • SIKLOS L, ENGLEHARDT J, HARATI Y et al.: Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis. Ann. Neurol (1996) 39:203–216.
  • MASUI Y, MOZAI T, KAKEHI K: Functional and morphometric study of the liver in motor neuron disease. I Neural. (1985) 232:15–19.
  • NAKANO Y, HIRAYAMA K, TERAO K: Hepatic ultrastructural changes and liver dysfunction in amyotrophic lateral sclerosis. Arch. Neural. (1987) 44:103–106.
  • WIEDEMANN FR, WINKLER K, KUZNETSOV A et al.: Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. Neural. Sci. (1998) 156:65–72.
  • FUJITA K, YAMAUCHI M, SHIBAYAMA K et al.: Decreased cytochrome coxidase activity but unchanged superoxide dismutase and glutathione peroxidase activities in the spinal cords of patients with amyotrophic lateral sclerosis. I Neurosci. Res. (1996) 45:276–281.
  • BROWNE SE, BOWLING AC, BAIK MJ et al: Metabolic dysfunction in familial, but not sproadic, amyotrophic lateral sclerosis. Neurochem. (1998) 71:281–287.
  • BECKMAN JS, BECKMAN TW, CHEN J, MARSHALL PA, FREEMAN BA: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Nati Acad. Sci. USA (1990) 87:1620–1624.
  • INCE P, STOUT N, SHAW P et al.: Parvalbumin and calbindin D-28K in the human motor system and in motor neuron disease. NeuropathoL Appi Neurobiol (1993) 19:291–299.
  • ALEXIANU ME, HO BK, MOHAMED AH et al: The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann. Neurol (1994) 36:846–858.
  • ELLIOTT JL, SNIDER WD: Parvalbumin is a marker of ALS-resistant motor neurons. NeuroReport (1995) 15:449–452.
  • SIKLOS L, ENGELHARDT JI, ALEXIANU ME et al: Intracellular calcium parallels motoneuron degeneration in SOD-1 mutant mice. j. Neuropathol Exp. Neural. (1998) 57:571–587.
  • KNIRSCH U, STURM S, REUTER A et al: Calcineurin A and calbindin immunoreactivity in the spinal cord of G93A superoxide dismutase transgenic mice. Brain Res. (2001) 889:234–238.
  • MANETTO V, STERNBERGER NH, PERRY G, STERNBERGER LA, GAMBETTI P: Phosphorylation of neurofilaments is altered in amyotrophic lateral sclerosis. J. Neuropathol Exp. Neurol (1988) 47:642–653.
  • MUNOZ DG, GREENE C, PERL DP, SELKOE DJ: Accumulation of phosphorylated neurofilaments in anterior horn motoneurons of amyotrophic lateral sclerosis patients. J. Neuropathol Exp. Neurol (1988) 47:9–18.
  • LEIGH PN, DODSON A, SWASH M, BRION J-P, ANDERTON BH: Cytoskeletal abnormalities in motor neuron disease. Brain (1989) 112:521–535.
  • MURAYAMA S, BOULDIN TW, SUZUKI K: Immunocytochemical and ultrastructural studies of upper motor neurons in amyotrophic lateral sclerosis. Acta Neuropathol (1992) 83:518–524.
  • WONG N, HE BP, STRONG MJ: Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis (ALS). Neuropathol Exp. Neurol (2000) 59:972–982.
  • BERGERON C, BERIC-MASKAREL K, MUNTASSER S et al: Neurofilament light and polyadenylated mRNA levels are decreased in amyotrophic lateral sclerosis motor neurons. NeuropathoL Exp. Neural. (1994) 53:221–230.
  • STRONG MJ, LEYSTRA-LANTZ C, GE W: Intermediate filament steady state mRNA levels in amyotrophic lateral sclerosis (ALS). Biochem. Biophys. Res. Comm. (2004) 316:317–322.
  • GE W, LEYSTRA-LANTZ C, WEN W, STRONG MJ: Selective loss of trans-acting instability determinants of neurofilament mRNA in amyotrophic lateral sclerosis spinal cord. J. Biol. Chem. (2003) 278:26558–26563.
  • LEE MK, MARSZALEK JR, CLEVELAND DW: A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron (1994) 13:975–988.
  • SCHWARTZ ML, BRUCE J, SHNEIDMAN PS, SCHLAEPFER WW: Deletion of 3'-untranslated region alters the level of mRNA expression of a neurofilament light subunit transgene. J. Biol. Chem. (1995) 270:26364–26369.
  • CANETE-SOLER R, SILBERG DG, GERSHON MD, SCHLAEPFER WW: Mutation in neurofilament transgene implicates RNA processing in the pathogenesis of neurodegenerative disease. Neurosci. (1999) 19:1272–1283.
  • LIN H, ZHAI J, CANETE-SOLER R, SCHLAEPFER WW: 3' Untranslated region in a light neurofilament (NF-L) mRNA triggers aggregation of NF-L and mutant superoxide dismutase 1 proteins in neuronal cells. Neurosci. (2004) 24:2716–2726.
  • STRONG MJ, SOPPER MM, HE BP: hi vitro reactive nitrating species toxicity in dissociated spinal motor neurons from NFL ( ) and hNFL (-4-) transgenic mice. Arnyotroph. Lateral Scler. Other Motor. Neuron. Disord. (2003) 11:81–89.
  • NGUYEN MD, LARIVIERE RC, JULIEN J-P: Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron (2001) 30:135–147.
  • BEAULIEU J-M, NGUYEN MD, JULIEN J-P: Late-onset death of motor neurons in mice overexpressing wild-type peripherin. J. Cell Biol. (1999) 147:531–544.
  • EKEGREN T, GRUNDSTROM E, LINDHOLM D, AQUILONIUS S-M: Upregulation of Bax protein and increased DNA degradation in ALS spinal cord motor neurons. Acta Neurol Scand. (1999) 100:317-321. zoo. MU X, HE J, ANDERSON DW, TROJANOWSKI JQ, SPRINGER JE: Altered expression of bc.T2 and bax mRNA in amyotrophic lateral sclerosis spinal cord motor neurons. Ann. Neurol (1996) 40:379–386.
  • DE LA MONTE SM, SOHN YK, GANJU N, WANDS JR: P53- and CD95-associated apoptosis in neurodegenerative diseases. Lab. Invest. (1998) 78:401-411. zoz. SATHASIVAM S, INCE PG, SHAW PJ: Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol Appl. Neurobiol (2001) 27:257–274.
  • MARTIN LJ: Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J. Neuropathol Exp. Neurol (1999) 58:459–471.
  • MARTIN LJ: p53 is abnormally elevated and active in the CNS of patients with amyotrophic lateral sclerosis. Neurobiol Dis. (2000) 7:613–622.
  • PEDERSEN WA, LUO H, KRUMAN I, KASARSKIS E, MATTSON MP: The prostate apoptosis response-4 protein participates in motor neuron degeneration in amyotrophic lateral sclerosis. FASEB (2000) 14:913-924. zos. VUKOSAVIC S, DUBOIS-DAUPHIN M, ROMERO N, PRZEDBORKSI S: Bax and Bc1-2 interaction in a transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. (1999) 73:2460–2468.
  • SHINOE T, WANAKA A, NIKAIDO T et al.: Upregulation of the pro-apoptotic BH3-only peptide harakiri in spinal neurons of amyotrophic lateral sclerosis patients. Neurosci. Lett. (2001) 313:153-157. zos. PANDEY P, SALEH A, NAKAZAWA A et al.: Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO (2000) 19:4310–4322.
  • BEERE HM, WOLF BB, CAIN K et al: Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat. Cell Biol. (2000) 2:469–475.
  • BRUEY JM, DUCASSE C, BONNIAUD P et al.: Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat. Cell Biol. (2000) 2:645–652.
  • LACOMBLEZ L, BENSIMON G, LEIGH PN et al: Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet (1996) 347:1425–1431.
  • RIVIERE M, MEININGER V, ZEISSER P, MUNSAT T: An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch. Neurol (1998) 55:526–528.
  • KALRA S, CASHMAN NR, GENGE A, ARNOLD DL: Recovery of N-acetylaspartate in corticomotor neurons in patients with ALS after riluzole therapy. NeuroReport (1998) 9:1757–1761.
  • MARAGAKIS NJ, JACKSON M, GANEL R, ROTHSTEIN JD: Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice. NeuroscL Lett. (2003) 338:107–110.
  • CUDKOWICZ ME, SHEFNER JM, SCHOENFELD DA et al.: A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology (2003) 61:434–435.
  • ALS CNTF TREATMENT STUDY GROUP: A double-blind, placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology(1996) 46:1244–1249.
  • MILLER RG, PETAJAN J, BRYAN WW et al.: A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann. Neurol (1996) 39:256–260.
  • LAI EC, FELICE KJ, FESTOFF BW et al: Effect of recombinant human insulin-like growth factor on progression of ALS. A placebo controlled study. Neurology (1997) 49:1621–1630.
  • ACKERMAN SJ, SULLIVAN EM, BEUSTERIEN KM et al: Cost effectiveness of recombinant human insulin-like growth Factor I therapy in patients with ALS. Pharmacoeconomics (1999) 15:179–195.
  • BORASIO GD, ROBBERECHT W, LEIGH PN et al: A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. Neurology (1998) 51:583–586.
  • OOSTHUYSE B, MOONS L, STORKEBAUM E et al.: Deletion of the hypwda-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. (2001) 28:131–138.
  • LAMBRECHTS D, STORKEBAUM E, MORIMOTO M et al: VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. (2003) 34:383–394.
  • AZZOUZ M, RALPH GS, STORKEBAUM E et al.: VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (2004) 429:413–417.
  • DEVOS D, MOREAU C, LASSALLE P et al.: Low levels of the vascular endothelial 1611 Expert Op/n. lnvestig. Drugs (2004) 13(12) growth factor in CSF from early ALS patients. Neurology (2004) 62:2127–2129.
  • ILZECKA J: Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis. Clin. Neurol Neurosurg. (2004) 106:289–293.
  • SPLIET WG, ARONICA E, RAMKEMA M et al: Immunohistochemical localization of vascular endothelial growth factor receptors-1, -2, and -3 in human spinal cord: altered expression in amyotrophic lateral sclerosis. Neuropathol Appl. Neurobiol (2004) 30:351–359.
  • LI B, XU W, LUO C, GOZAL D, LIU R: VEGF-induced activation of the P13-K/Akt pathway reduces mutant SOD1-mediated motor neuron cell death. Ma Brain Res. (2003) 111:155–164.
  • KRIZ J, GOWING G, JULIEN J-P: Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann. Neurol (2003) 53:429–436.
  • BEN HAMIDA M, HENTATI F, BEN HAMIDA C: Hereditary motor system diseases (chronic juvenile amyotrophic lateral sclerosis). Brain (1990) 113:347–363.
  • HENTATI A, BEJAOUI K, PERICAK-VANCE MA et al.: Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-q35. Nat.Genet. (1994) 7:425–428.
  • HOSLER BA, SAPP PC, BERGER R et al: Refined mapping and characterization of the recessive familial amyotrophic lateral sclerosis locus (ALS2) on chromosome 2q33. Neurogenetics (1998) 2:34–42.
  • SIDDIQUE T, FIGLEWICZ DA, PERICAK-VANCE MA et al.: Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity. N Engl. Med. (1991) 324:1381–1384.
  • HAND CK, KHORIS J, SALACHAS F et al.: A novel locus for familial amyotrophic lateral sclerosis on chromosome 18q. Am. J. Hum. Genet. (2002) 70:251–256.
  • HENTATI A, OUAHCHI K, PERICAK-VANCE MA et al.: Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers. Neurogenetics (1998) 2:55–60.
  • SAPP PC, HOSLER BA, McKENNA-YASEK D et al: Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. Am. J. Hum. Genet. (2003) 73:397–403.
  • RUDDY DM, PARTON MJ, AL-CHALABI A et al.: Two families with familal amyotrophic lateral sclerosis are linked to a novel locus on chromosome 16q. Am. Hum. Genet. (2003) 73:396.
  • ABALKHAIL H, MITCHELL J, HABGOOD J, ORRELL R, DE BELLEROCHE J: A new familial amyotrophic lateral sclerosis locus on chromosome 16q12.1-16q12.2. Am. J. Hum. Genet. (2003) 73:383–389.
  • NISHIMURA AL, MITNE-NETO M, SILVA HCA et al: A novel locus for late onset amyotrophic lateral sclerosis/motor neurone disease variant at 20q13. Med. Genet. (2004) 41:315–320.
  • HOSLER BA, SIDDIQUE T, SAPP PC et al.: Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA (2000) 284: 1664-1669.
  • WILHELMSEN KC, FORMAN MS, ROSEN HJ et al.: 17q-Linked frontotemporal dementia-amyotrophic lateral sclerosis without tau mutations with tau and a-synuclein inclusions. Arch. Neural. (2004) 61:398–406.
  • OTERO SILICEO E, ARRIADA-MENDICOA N, BALDERRAMA J : Juvenile familial amyotrophic lateral sclerosis: four cases with long survival. Dev. Med. Child Nemo]. (1998) 40:425–428.
  • BROWN CH: Infantile amyotrophic lateral sclerosis of the family type. Nerv. Mental Dis. (1894) 21:707–716.
  • VAN LAERE MJ: Paralysie bulbo-pontine chronique progressive familiale aver surdité. Un cas de syndrome de Klippel-Trenaunay dans la même fratrie. Problemes diagnostiques et génétiques. Rev Neurol (1966) 115:289–295.
  • VIALETTO E: Contributo alla forma ereditaria della paralisi bulbare progressiva. Riv. Spec Frenait. (1936) 40:1–24.
  • HAWKINS SA, NEVIN NC, HARDING AE: Pontobulbar atrophy and neurosensory deafness (Brown-Vialetto-Van Laere syndrome) with possible autosomal dominant inheritance. J Med. Genet. (1990) 27:176–179.
  • KENNEDY WR, ALTER M, SUNG JH: Progressive proximal spinal and bulbar muscular atrophy of late onset. Neurology (1968) 18:671–680.
  • HARDING AE, THOMAS PK, BARAITSER M et al.: X-linked recessive bulbospinal neuronopathy: a report of ten cases. Neurol Neurosurg. Psychiat. (1982) 45:1012–1019.
  • LA SPADA AR, WILSON EM, LUBAHN DB, HARDING AE, FISCHBECK KH: Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature (1991) 352:77–79.
  • PARBOOSINGH JS, FIGLEWICZ D, KRIZUS A et al.: Spinobulbar muscular atrophy can mimic ALS: the importance of genetic testing in male patients with atypical ALS. Neurology (1998) 49:568–572.
  • STRONG MJ: The basic aspects of therapuetics in amyotrophic lateral sclerosis. Pharmacol The]: (2003) 98:379–414.
  • BENSIMON G, LACOMBLEZ I, MEININGER V, THE ALS/RILUZOLE STUDY GROUP: A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl. J. Med. (1994) 330:585–591.
  • BLIN 0, POUGET J, AUBRESPY G et al: A double-blind, placebo-controlled trial of L-threonine in amyotrophic lateral sclerosis. Neurol (1992) 239:79–81.
  • TESTA D, CARACENI T, FETONI V, GIROTTI F: Chronic treatment with L-threonine in amyotrophic lateral sclerosis: a pilot study. an. Neuro/. Neurosurg. (1992) 94:7–9.
  • TANDAN R, BROMBERG MB, FORSHEW DA et al: A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data. Neurology (1996) 47:1220–1226.
  • THE ITALIAN ALS STUDY GROUP: Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? Neurology (1993) 43:2466–2470.
  • TESTA D, CARACENI T, FETONI V: Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis. Neurol (1989) 236:445–447.
  • MILLER RG, MOORED, YOUNG LA et al.: Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology (1996) 47:1383–1388.
  • MILLER RG, MOORE DH2, GELINAS DF et al.: Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology (2001) 56:843–848.
  • KALRA S, CASHMAN NR, CARAMANOS Z, GENGE A, ARNOLD DL: Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy. Am. j Neuroradiol (2003) 24:476–480.
  • EISEN A, STEWART H, SCHULZER M, CAMERON D: Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine. Can. Neurol Sci. (1993) 20:301.
  • MILLER RG, SMITH SA, MURPHY JR et al.: A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle Nerve (1996) 19:511–515.
  • GREDAL 0, WERDELIN L, BAK S et al: A clinical trial of dextromethorphan in amyotrophic lateral sclerosis. Acta Neurol Scand. (1997) 96:8–13.
  • ASKMARK H, AQUILONIUS S-M, GILLBERG P-G et al.: A pilot trial of dextromethorphan in amyotrophic lateral sclerosis. Neurol Neurosurg. Psychiat. (1993) 56:197–200.
  • BLIN 0, AZULAY JP, DESNUELLE C et al.: A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis. Clin. Neuropharmacol (1996) 19:189–192.
  • MILLER RG, SHEPHERD R, DAO H et al.: Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromusc. Disord. (1996) 6:101–104.
  • LOUWERSE ES, WEVERLING GJ, BOSSUYT PMM, MEYJES FEP, DE JONG JMBV: Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch. Neurol (1995) 52:559–564.
  • DESNUELLE C, DIB M, GARREL C, FAVIER A: A double-blind, placebo-controlled randomized clinical trial of alphs-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol study group. Amyotroph. Lateral Scler. Other Motor. Neuron. Disond (2001) 2:9–18.
  • CHIO A, CUCATTO A, TERRENI AA, SCHIFFER D: Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial. Ital. .1 Neurol Sci. (1998) 19:363–366.
  • MAZZINI L, TESTA D, BALZARINI C, MORA G: An open-randomized clinical trial of selegeline in amyotrophic lateral sclerosis. Neurol (1994) 241:223–227.
  • JOSSAN SS, EKBLOM J, GUDJONSSON 0, HAGBARTH K-E, AQUILONIUS S-M: Double blind Cross over trial with deprenyl in amyotrophic lateral sclerosis.' Neural Trans. (1994) 41:237–241.
  • LANGE DJ, MURPHY PL, DIAMOND B et al.: Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch. Neurol (1998) 55:93–96.
  • GROENEVELD GJ, VELDINK JH, VAN DER TWEEL I et al: A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann. Neurol (2003) 53:437–445.
  • CUDKOWICZ ME, WARREN L, FRANCIS JVV et al.: Intrathecal administration of recombinant human superoxide dismutase 1 in amyotrophic lateral sclerosis: a preliminary safety and pharmacokinetic study. Neurology (1997) 49:213–222.
  • SMITH RA, MELMED S, SHERMAN B et al.: Recombinant growth hormone treatment of amyotrophic lateral sclerosis. Muscle Nerve (1993) 16:624–633.
  • BROOKE MH, FLORENCE JM, HELLER SL et at Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis. Neurology (1986) 36:146–151.
  • MITSUMOTO H, SALGADO ED, NEGROSKI D et al: Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials. Neurology(1986) 36:159.
  • IMOTO K, SAIDA K, IWAMURA K, SAIDA T, NISHITANI H: Amyotrophic lateral sclerosis: a double-blind crossover trial of thyrotropin-releasing hormone. Neurol Neurosurg. Psychiat. (1984) 47:1332–1334.
  • CAROSCIO JT, COHEN JA, ZAWODNIAK J et al: A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis. Neurology (1986) 36:141–145.
  • MUNSAT TL, TAFT J, JACKSON IM et al.: Intrathecal thryotropin-releasing hormone does not alter the progressive course of ALS: Experience with an intrathecal drug delivery system. Neurology (1992) 42:1049–1053.
  • KASARSKIS EJ, THE BDNF STUDY GROUP (PHASE III): A controlled trial of recombinant methionyl human BDNF in ALS. Neurology (1999) 52:1427–1433.
  • BROWN RH Jr, HAUSER SL, HARRINGTON H, WEINER HL: Failure of immunosuppression with a 10- to 14-day course of high-dose intravenous cyclophosphamide to alter the progression of amyotrophic lateral sclerosis. Arch. Neurol (1986) 43:383–384.
  • GOURIE-DEVI M, NALINI A, SUBBAKRISHNA DK: Temporary amelioration of symptoms with intravenous cyclophosphamide in amyotrophic lateral sclerosis. Neurol ScL (1997) 150:167–172.
  • TAN E, LYNN J, AMATO AA et al: Immunosuppressive treatment of motor neuron syndromes. Arch.Neurol (1994) 51:194–200.
  • MEUCCI N, NOBILE-ORAZIO E, SCARLATO G: Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. I Neurol (1996) 243:117–120.
  • DALAKAS MC, STEIN DP, OTERO C et al.: Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy. Arch. Neurol (1994) 51:861–864.
  • OLARTE MR, SCHOENFELDT RS, McKIERNAN G, ROWLAND LP: Plasmapheresis in amyotrophic lateral sclerosis. Ann. Neurol (1980) 8:644–645.
  • KELEMEN J, HEDLUND W, ORLIN JB, BERKMAN EM, MUNSAT TL: Plasmapheresis with immunosuppression in amyotrophic lateral sclerosis. Arch. Neurol (1983) 40:752–753.
  • DRACHMAN DB, CHAUDHRY V, CORNBLATH DR et al.: Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann. Neurol (1994) 35:142–150.
  • HAVERKAMP LJ, SMITH RG, APPEL SH: Trial of immunosuppression in amyotrophic lateral sclerosis using total lymph node irradiation. Ann. Neurol (1994) 36:253-254. zso. APPEL SH, STEWART SS, APPEL V et al.: A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch. Neurol (1988) 45:381–386.
  • BEGHI E, CHIC) A, INGHILLERI M et al.: A randomized controlled trial of 1613 Expert Op/n. lnvestig. Drugs (2004) 13(12) recombiant interferon 13- la in ALS. Neurology (2000) 54:469–474.
  • MORA JS, MUNSAT TL, KAO K-P et al: Intrathecal administration of natural human interferon alpha in amyotrophic lateral sclerosis. Neurology (1986) 36:1137–1140.
  • MENDELL JR, CHASE TN, ENGEL WK: Amyotrophic lateral sclerosis. A trial of central monoamine metabolism and therapeutic trial of levodopa. Arch. Neurol (1971) 25:320–325.
  • NORRIS FH, TAN Y, FALLAT RJ, ELIAS L: Trial of oral physostigmine in amyotrophic lateral sclerosis. Clio. PharmacolTher. (1993) 54:680–682.
  • AQUILONIUS S-M, ASKMARK H, ECKERNAS S-A et al.: Cholinesterase inhibitors lack therapeutic effect in amyotrophic lateral sclerosis. A controlled study of physostigmine versus neostigmine. Acta Neurol Scand. (1986) 73:628–632.
  • AISEN ML, SEVILLA D, EDELSTEIN L, BLASS J: A double-blind placebo-controlled study of 3,4-diaminopyridine in amyotrophic lateral sclerosis patients on a rehabilitation unit. Neurol Sci. (1996) 138:93–96.
  • ASKMARK H, AQUILONIUS S-M, GILLBERG P-G et al.: Functional and pharmacokinetic studies of tetrahydroaminoacridine in patients with amyotrophic lateral sclerosis. Acta Neurol Scand. (1990) 82:253–258.
  • OLSON WH, SIMONS JA, HALAAS GW: Therapeutic trial of tilorone in ALS: lack of benefit in a double-blind, placebo-controlled study. Neurology (1978) 28:1293–1295.
  • RIVERA VM, GRABOIS M, DEATON W, BREITBACH W, HINES M: Modified snake venom in amyotrophic lateral sclerosis. Arch. Neurol (1980) 37:201–203.
  • LACOMBLEZ L, BOUCHE P, BENSIMON G, MEININGER V: A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis. Neurology (1989) 39:1635–1637.
  • BRADLEY WG, HEDLUND W, COOPER C et al.: A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis. Neurology (1984) 34:1079–1082.
  • HARRINGTON H, HALLET M, TYLER HR: Ganglioside therapy for amyotrophic lateral sclerosis: a double-blind controlled trial. Neurology (1984) 34:1083–1085.
  • HALLETT M, HARRINGTON H, TYLER HR, FLOOD T, SLATER N: Trials of ganglioside therapy for amyotrophic lateral sclerosis and diabetic neuropathy. Adv. Exp. Med. Biol. (1984) 174:575–579.
  • MUNSAT TL, EASTERDAY CS, LEVY S, WOLFF SM, HIATT R: Amantadine and guanidine are ineffective in ALS. Neurology (1981) 31:1054-1055. Websites

Websites

  • http://www.statcan.ca/english/Pgdb/ demo23a.htm Statistics Canada, CANSIM, Table 052–0001.
  • http://www.ncbi.nlm.nih.gov/Omim Online mendelian inheritance in man.
  • http://www.alsod.org The ALS online database.
  • http://www.stke.org/cgi/content/full/ OC_sigtrans;2001/93/rel BEERE HM: Stressed to death: regulation of apoptotic signaling pathways by heat shock proteins. SciStke (2001)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.